Clinical Trials

Pfizer begins Phase I clinical trial of mRNA influenza vaccine

Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology.

Hookipa, Merck partner for Phase II HB-200/Keytruda combination trial

Hookipa Pharma has signed a clinical collaboration and supply agreement with Merck to assess HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck squamous cell carcinoma (HNSCC).

EnGeneIC begins Phase I trial of nanocellular vaccine for Covid-19

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults.

Centivax signs strategic collaboration with US NMRC for Covid-19 antibody

Centivax has inked a strategic collaboration with the US Naval Medical Research Center (NMRC) to carry out Phase I trial of Centi-B9, its SARS-CoV-2 antibody.

Study finds PARP inhibitors kill cancer cells with defect in PBRM1 gene

A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells with a particular defect in the PBRM1 gene.

Claritas and CMAX Clinical sign agreement for Phase 1 R-107 clinical study

Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107.

Antengene announces China’s NMPA approval for IND application for ATG-019 clinical trial

Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).

UCLA-led lab study identifies potential drug to treat SARS-CoV-2 virus

A study led by the University of California, Los Angeles (UCLA) has identified a compound, berzosertib, which showed potential in treating SARS-CoV-2 virus which causes Covid-19.

AstraZeneca to deliver 500,000 more doses of AZD7442 to US

The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.